白蛋白结合型紫杉醇联合铂类治疗复发转移性头颈部鳞癌的临床效果及对肿瘤标志物水平的影响

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (605 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

目的研究白蛋白结合型紫杉醇联合铂类治疗复发转移性头颈部鳞癌的临床效果及对肿瘤标志物水平的影响。方法选取2019年6月至2020年12月南通市通州区人民医院肿瘤科及南通大学附属肿瘤医院放疗科收治的60 例复发转移性头颈部鳞癌患者作为研究对象，采用抛硬币法将其随机分为对照组与观察组，每组各30 例。对照组患者采用紫杉醇联合铂类化疗，观察组患者采用白蛋白结合型紫杉醇联合铂类化疗。比较两组患者的近期疗效、治疗前后的血清肿瘤标志物[血清鳞状细胞癌相关抗原（SCC）、癌胚抗原（CEA）、血管内皮生长因子（VEGF）]水平及不良反应发生率。结果观察组患者的疾病控制率（DCR）为80.00%，高于对照组的53.33%，差异有统计学意义（P＜0.05）。两组患者治疗后的SCC、CEA、VEGF 水平均低于治疗前，差异有统计学意义（P＜0.001）。观察组患者治疗后的SCC、CEA、VEGF 水平均低于对照组，差异有统计学意义（P＜0.05）。观察组患者的不良反应总发生率为50.00%，低于对照组的76.67%，差异有统计学意义（P＜0.05）。结论白蛋白结合型紫杉醇联合铂类用于复发转移性头颈部鳞癌中近期疗效确切，可降低肿瘤标志物水平，不良反应可控，值得推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王娟
	曹剑锋
	何云华
	单桂芹
	葛方红

关键词 ：白蛋白结合型紫杉醇, 铂类, 复发转移性, 头颈部鳞癌, 肿瘤标志物

Abstract：

Objective To study the effect of Albumin-bound Paclitaxel combined with Platinum on the clinical efficacy and tumor marker levels of recurrent and metastatic head and neck squamous cell carcinoma. Methods A total of 60 patients with recurrent and metastatic head and neck squamous cell carcinoma admitted to Tongzhou District People's Hospital of Nantong City and Cancer Hospital Affiliated to Nantong University from June 2019 to December 2020 were selected as the research objects and randomly divided into the control group and the observation group by coin flipping, with 30 cases in each group. The control group was treated with Paclitaxel combined with Platinum chemotherapy,and the observation group was treated with Albumin-bound Paclitaxel combined with Platinum chemotherapy. The short-term efficacy, the levels of tumor markers serum (squamous cell carcinoma-associated antigen [SCC],carcinoembryonic antigen [CEA], and vascular endothelial growth factor [VEGF]) before and after treatment and the incidence of adverse reactions were compared. Results The disease control rate (DCR) of the observation group was 80.00%, which was higher than that of the control group (53.33%), and the difference was statistically significant (P<0.05). After treatment, the levels of SCC, CEA and VEGF in the two groups were lower than those before treatment, and the differences were statistically significant (P<0.05). After treatment, the levels of SCC, CEA and VEGF in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.001). The incidence of adverse reactions in the observation group was 50.00%, which was lower than 76.67%in the control group, and the difference was statistically significant (P<0.05). Conclusion The combination of Albumin-bound Paclitaxel and Platinum for recurrent and metastatic head and neck squamous cell carcinoma has a definite short-term curative effect, which can reduce the level of tumor markers, and the adverse reactions are controllable.It is worthy of promotion.

Key words： Albumin-bound Paclitaxel Platinum Recurrent and metastatic Head and neck squamous cell carcinoma;Tumor markers

基金资助:

江苏省南通市卫生健康委员会科研课题（QA201 9053）。

通讯作者: 葛方红（1979-），女，汉族，江苏南通人，副主任医师，研究方向：头颈部肿瘤放化疗。

作者简介: 王娟（1984-），女，汉族，江苏宿迁人，硕士，副主任医师，研究方向：恶性肿瘤综合治疗与临床研究。

引用本文:

王娟; 曹剑锋; 何云华; 单桂芹; 葛方红. 白蛋白结合型紫杉醇联合铂类治疗复发转移性头颈部鳞癌的临床效果及对肿瘤标志物水平的影响[J]. 中国当代医药, 2022, 29(18): 18-21.
WANG Juan; CAO Jianfeng; HE Yunhua; SHAN Guiqin;GE Fanghong. Clinical effect of Albumin-bound Paclitaxel combined with Platinum in the treatment of recurrent and metastatic head and neck squamous cell carcinoma and the level of tumor markers. 中国当代医药, 2022, 29(18): 18-21.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I18/18

[1]	周旋，任玉，乔宇.STAT3 在头颈部鳞癌中的研究进展[J].天津医药，2020，48（6）：563-567.
[2]	Pi L，Zhu G，She L，et al.Elevated expression of derlin-1 associates with unfavorable survival time of squamous cell carcinoma of the head and neck and promotes its malignance[J].J Cancer，2017，8（12）：2336-2345.
[3]	于克娜，孙凯月，张杰，等.西妥昔单抗治疗头颈部鳞状细胞癌差异表达基因的生物信息学分析[J].山东大学耳鼻喉眼学报，2020，34（4）：117-124.
[4]	林建光，许天文，傅德强，等.白蛋白结合型紫杉醇一线治疗40 例晚期肺鳞癌的观察[J].中国肿瘤临床，2018，45（8）：394-397.
[5]	刘蓉，刘进，邢育珍.白蛋白结合型紫杉醇与多西他赛用于局部晚期舌鳞状细胞癌新辅助化疗的疗效观察[J].中华实用诊断与治疗杂志，2020，34（4）：411-413.
[6]	郭伟，任国欣，王志国.头颈部恶性肿瘤诊断治疗指南[J].中华口腔医学杂志，2006，41（8）：453-455.
[7]	Dewys WD，Begg C，Lavin PT，et al.Prognostic effect of weight loss prior to chemotherapy in cancer patients[J].Am J Med，1980，69（4）：491-497.
[8]	杨学宁，吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学，2004，4（2）：85-90.
[9]	Kautio AL，Haanpaa M，Kautiainen H，et al.Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy[J].Anticancer Res，2011，31（10）：3493-3496.
[10]	Ferreira PB，Redman M，Baker KK，et al.Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma[J].Laryngoscope，2017，127（7）：1583-1588.
[11]	李旭，艾斌，张萍，等.以白蛋白结合型紫杉醇为基础的方案治疗晚期肺癌的临床疗效及安全性观察[J].中国肺癌杂志，2017，20（7）：479-484.
[13]	郑璐，胡静，叶栋，等.局部晚期头颈部鳞癌患者血清肿瘤标志物水平对尼妥珠单抗近期疗效及预后的预测价值[J].中国现代应用药学，2020，37（11）：1365-1369.
[16]	熊云棋，狄文，吴霞.白蛋白结合型紫杉醇联合铂类或异环磷酰胺治疗复发性卵巢癌的疗效及安全性分析[J].现代妇产科进展，2017，26（5）：325-332.
[18]	王芸，张耕源，罗长江，等.白蛋白结合型紫杉醇联合吉西他滨治疗进展期胰腺癌临床效果的Meta 分析[J].临床肝胆病杂志，2019，35（5）：1041-1046.
[12]	Ley J，Wildes TM，Daly K，et al.Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophorbased paclitaxel or docetaxel[J].Med Oncol，2017，34（2）：28.
[14]	Peurala E，Tuominen M，Loyttyniemi E，et al.Eosinophilia is a favorable prognostic marker for oral cavity and lip squamous cell carcinoma[J].APMIS，2018，126（3）：201-207.
[15]	Higuchi M，Takagi H，Owada Y，et al.Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer：a multi-center study of the fukushima lung cancer association group of surgeons[J].Oncol Letts，2017，13（6）：4315-4321.
[17]	Zong Y，Wu J，Shen K.Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer：a systematic review and meta-analysis[J].Oncotarget，2017，8（10）：17 360-17 372.